These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21152861)

  • 41. Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.
    Cao W; Yang Q; Yuan Z; Li H; Wang W; Xiao X; Wang Z; Liang L; Zhou P; Liu J; Hu X; Zhang B
    Biochem Biophys Res Commun; 2020 Apr; 524(3):549-554. PubMed ID: 32014255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
    Tooker P; Yen WC; Ng SC; Negro-Vilar A; Hermann TW
    Cancer Res; 2007 May; 67(9):4425-33. PubMed ID: 17483357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
    Siena L; Pace E; Ferraro M; Di Sano C; Melis M; Profita M; Spatafora M; Gjomarkaj M
    Immunology; 2014 Feb; 141(2):242-55. PubMed ID: 24128051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy.
    Goldmann T; Drömann D; Radtke J; Marwitz S; Lang DS; Schultz H; Vollmer E
    Virchows Arch; 2008 Mar; 452(3):347-8. PubMed ID: 18214534
    [No Abstract]   [Full Text] [Related]  

  • 45. Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells.
    Takahashi R; Sato T; Klinman DM; Shimosato T; Kaneko T; Ishigatsubo Y
    Int J Oncol; 2013 Feb; 42(2):429-36. PubMed ID: 23291718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
    Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
    Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.
    Zhang Y; Schwerbrock NM; Rogers AB; Kim WY; Huang L
    Mol Ther; 2013 Aug; 21(8):1559-69. PubMed ID: 23774791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.
    Kurdow R; Schniewind B; Zoefelt S; Boenicke L; Boehle AS; Dohrmann P; Kalthoff H
    Langenbecks Arch Surg; 2005 Jun; 390(3):243-8. PubMed ID: 15726400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
    Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
    Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines.
    Pace E; Melis M; Siena L; Bucchieri F; Vignola AM; Profita M; Gjomarkaj M; Bonsignore G
    Cancer Chemother Pharmacol; 2000; 46(6):467-76. PubMed ID: 11138460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.
    Sève P; Mackey JR; Isaac S; Trédan O; Souquet PJ; Pérol M; Cass C; Dumontet C
    Lung Cancer; 2005 Sep; 49(3):363-70. PubMed ID: 15923058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
    Kim MK; Jeon YK; Woo JK; Choi Y; Choi DH; Kim YH; Kim CW
    Mol Cancer; 2011 Aug; 10():98. PubMed ID: 21843371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer.
    Liu Y; Miao L; Ni R; Zhang H; Li L; Wang X; Li X; Wang J
    Oncol Rep; 2016 Dec; 36(6):3529-3535. PubMed ID: 27748920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
    Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.
    Samakoglu S; Deevi DS; Li H; Wang S; Murphy M; Bao C; Bassi R; Prewett M; Tonra JR
    Cancer Genomics Proteomics; 2012; 9(2):77-92. PubMed ID: 22399498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
    Cheng CY; Cherng SH; Wu WJ; Yang TY; Huang XY; Liao FT; Wu MF; Sheu GT
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):145-54. PubMed ID: 21630085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.